|1.||Lutgens, Esther: 15 articles (06/2015 - 01/2002)|
|2.||Aukrust, Pål: 15 articles (02/2015 - 01/2003)|
|3.||Libby, Peter: 15 articles (11/2011 - 12/2002)|
|4.||Davì, Giovanni: 13 articles (07/2015 - 07/2002)|
|5.||Xiang, Jim: 10 articles (11/2015 - 02/2002)|
|6.||Varo, Nerea: 10 articles (06/2012 - 12/2002)|
|7.||Schönbeck, Uwe: 10 articles (04/2010 - 12/2002)|
|8.||Santilli, Francesca: 9 articles (07/2015 - 01/2006)|
|9.||Violi, Francesco: 9 articles (11/2014 - 01/2005)|
|10.||Pignatelli, Pasquale: 9 articles (11/2014 - 01/2005)|
07/01/2008 - "CD40/CD40L signaling promotes both B cell and CTL responses in vivo, the latter being beneficial in tumor models. "
11/01/1997 - "Mice injected with cells that expressed CD40L had a significant reduction in average tumor size as compared to controls (p < 0.0001). "
02/01/1997 - "The understanding of the biology of CD40L has improved our diagnostic and therapeutic repertoire in the management of several human diseases, including CD40+ tumors."
04/01/2014 - "AdCD40L therapy introduces the CD40L gene into the tumor microenvironment with an adenoviral vector and has shown promising results in experimental tumor models, dogs, and patients (phase I-II trials). "
01/01/2014 - "Targeted delivery of CD40L to cancer cells is a promising strategy that may help to trigger cancer-localized activation of CD40 and can be modified to exert additional anti-cancer activity via the targeting domain."
03/15/2013 - "Most C57 mice eliminated the strain within 3 days whereas infection remained in C57-cd40l(-/-) mice until day 14. "
09/01/2014 - "Our results demonstrated that the CD40L adjuvant enhanced the functional quality of anti-Env antibody response and breadth of anti-SIV CD8 and CD4 T cell responses, significantly delayed the acquisition of heterologous mucosal SIV infection, and improved viral control. "
04/20/1998 - "To study the role of CD40L in mediating protection against infection with H. "
10/01/2005 - "Transfection of Trypanosoma cruzi with host CD40 ligand results in improved control of parasite infection."
05/15/2014 - "In this study we show that soluble CD40 ligand also promotes the formation of complexes between inflammatory monocytes and activated platelets (PMCs), which are detected by flow cytometry as monocytes that express excess of CD61, a platelet marker, and that these complexes are increased in individuals with HIV-1 infection. "
09/01/2011 - "We tested the hypothesis that soluble CD40 ligand (sCD40L), a biomarker of proatherogenic inflammation, may be predictive of cardiovascular (CV) events in a subgroup of patients from the RISCAVID study, an observational and prospective study in patients on haemodialysis (HD). "
07/01/2006 - "Recent studies have demonstrated that PLTs promote immunity and inflammation mainly by means of the CD40/CD40L pathway. "
02/01/2006 - "Recent studies suggest that CD40-CD40 ligand (CD40L) system is proven to be an important mediator of several auto-immune and chronic inflammation diseases. "
01/01/2006 - "The aim of the study was estimation of a concentration soluble form of CD40, CD40L (CD154) in the bacterial and viral inflammation of the central nervous system in two compartments - blood circulation and intrathecally, before and after the treatment. "
01/01/2003 - "These data provide novel insight into the mechanism through which elevated levels of soluble CD40 ligand may reflect cardiovascular risk in humans and illustrate the potential value of interfacing high-resolution MRI with studies of vascular inflammation."
|4.||Atherosclerotic Plaque (Atheroma)
01/01/2003 - "Soluble CD40 ligand levels indicate lipid accumulation in carotid atheroma: an in vivo study with high-resolution MRI."
06/01/2008 - "The CD40/CD40L system is considered a crucial modulator of the inflammatory process underlying the progression and complication of atheroma plaques. "
05/01/2007 - "TRAF-1, -2, -3, -5, and -6 are induced in atherosclerotic plaques and differentially mediate proinflammatory functions of CD40L in endothelial cells."
12/01/2005 - "However, atherosclerotic plaque progression and plaque phenotype did not change in LDLR(-/-) mice reconstituted with CD40L(-/-) BM. "
12/01/2013 - "CD40/CD40L, OX40L/OX40, CD70/CD27 and CD137/CD137L are present in human atherosclerotic plaques and have shown strong immune modulatory functions in atherosclerosis, resulting in either atherogenic or atheroprotective effects in mouse models of atherosclerosis. "
|5.||Hepatocellular Carcinoma (Hepatoma)
06/01/2012 - "Enhanced immunity against hepatoma induced by dendritic cells pulsed with Hsp70-H22 peptide complexes and CD40L."
03/01/2009 - "Growing role of CD40 ligand gene transfer therapy in the management of systemic malignancies besides hepatocellular carcinomas."
10/01/2008 - "Adenovirus-mediated CD40L gene therapy induced both humoral and cellular immunity against rat model of hepatocellular carcinoma."
01/14/2005 - "To construct a recombinant murine CD40 ligand (mCD40L) eukaryotic expression vector for gene therapy and target therapy of hepatocellular carcinoma (HCC). "
02/01/2003 - "However little is known about antitumor activity of Ftl3L and CD40L against hepatocellular carcinoma (HCC). "
|1.||CD40 Ligand (CD40L)
|3.||Interleukin-12 (IL 12)
|4.||Chemokine CCL2 (Monocyte Chemoattractant Protein 1)
|7.||Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
|10.||Interleukin-4 (Interleukin 4)
|3.||Drug Therapy (Chemotherapy)